BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28589759)

  • 21. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinical update in polycythemia vera and essential thrombocythemia.
    Tefferi A; Solberg LA; Silverstein MN
    Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
    Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
    Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MPN blast phase: clinical challenge and assessing response.
    Mesa RA; Tibes R
    Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
    [No Abstract]   [Full Text] [Related]  

  • 26. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
    Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
    Tallarico M; Odenike O
    Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
    Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
    Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing disease burden in patients with classic MPNs.
    Geyer H; Mesa RA
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
    Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
    Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
    Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
    Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
    Geyer HL; Dueck AC; Scherber RM; Mesa RA
    Mediators Inflamm; 2015; 2015():284706. PubMed ID: 26538823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
    Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
    Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
    Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.
    Gross-Davis CA; Heavner K; Frank AL; Newschaffer C; Klotz J; Santella RM; Burstyn I
    Int J Environ Res Public Health; 2015 Feb; 12(3):2465-85. PubMed ID: 25719551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
    Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
    Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.
    Noor SJ; Tan W; Wilding GE; Ford LA; Barcos M; Sait SN; Block AW; Thompson JE; Wang ES; Wetzler M
    Leuk Res; 2011 May; 35(5):608-13. PubMed ID: 20727590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.